




Instance: composition-en-d5d0f8dae3251797998b53d83d0b35fa
InstanceOf: CompositionUvEpi
Title: "Composition for lyfnua Package Leaflet"
Description:  "Composition for lyfnua Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/21/1613/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd5d0f8dae3251797998b53d83d0b35fa)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - lyfnua"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Lyfnua is and what it is used for</li>
<li>What you need to know before you take Lyfnua</li>
<li>How to take Lyfnua</li>
<li>Possible side effects</li>
<li>How to store Lyfnua</li>
<li>Contents of the pack and other information</li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What lyfnua is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What lyfnua is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lyfnua contains the active substance gefapixant.
Lyfnua is a medicine used in adults for chronic cough (cough that lasts longer than 8 weeks) and:
* the cough does not go away even after using other medicines or
* the reason for the cough is unknown.
The active substance in Lyfnua, gefapixant, blocks the action of nerves that trigger abnormal
coughing.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take lyfnua"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take lyfnua"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Lyfnua
- if you are allergic to gefapixant or any of the other ingredients of this medicine (listed in section
6).
Warnings and precautions
Talk to your doctor or pharmacist before and while taking Lyfnua if you:</p>
<ul>
<li>are allergic to medicines containing sulphonamide</li>
<li>have sleep apnoea   where your breathing stops and starts while you sleep</li>
<li>develop an acute infection of the lung / lower respiratory system (e.g., pneumonia or
bronchitis) </li>
<li>experience change in how things taste, loss of taste, or being less able to taste, that continues
even after you stop taking Lyfnua 
Children and adolescents
Do not give this medicine to children and adolescents below the age of 18 years. This is because it has
not been studied in this age group.
Other medicines and Lyfnua
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other
medicines.
Pregnancy and breast-feeding
It is not known if Lyfnua can harm your unborn baby. Therefore, it is better to avoid use of Lyfnua if
you are pregnant.
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or
pharmacist for advice before taking this medicine.
Animal studies have shown that Lyfnua may pass into breast milk. A risk for your baby cannot be
excluded. You and your doctor should decide together if you will take Lyfnua or breastfeed.
Driving and using machines
You may feel dizzy after taking Lyfnua. If this happens, do not drive or use tools or machines until
you no longer feel dizzy.
Lyfnua contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium
free .</li>
</ul> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take lyfnua"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take lyfnua"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor
or pharmacist if you are not sure.
How much to take
The recommended dose of Lyfnua is:</p>
<ul>
<li>
<p>one 45 mg tablet twice every day.
Adults with kidney problems
Your doctor may change how much and how often you take Lyfnua if:</p>
</li>
<li>
<p>you have severe kidney failure and are not on dialysis.
How to take
Swallow the tablet whole. Do not break, crush, or chew the tablet.
You can take the tablet with or without food.
If you take more Lyfnua than you should
If you take too much Lyfnua, talk to a doctor or pharmacist straight away.
If you forget to take Lyfnua
If you miss a dose, skip that dose and take the next dose at the scheduled time.
Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
</li>
</ul> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
The possible side effects are:
Very common (may affect more than 1 in 10 people)
- change in how things taste (such as a: metallic, bitter, or salty taste)
- being less able to taste
- loss of taste
Common (may affect up to 1 in 10 people)
- feeling sick (nausea)
- things tasting different than before
- cough (worsening, increase)
- dry mouth
- upper respiratory tract infection (an infection in the upper part of the airways including the nose
and throat)
- diarrhoea
- pain in your mouth or throat
- feeling less hungry than usual
- feeling dizzy
- upper abdominal (belly) pain 
- indigestion
- unusual feeling in mouth (e.g., tingling or prickling sensation)
- loss of feeling in the mouth
- increased saliva production
- insomnia (difficulty in sleeping)
Uncommon (may affect up to 1 in 100 people)
- bladder, urinary or kidney stones
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via the national reporting system
listed in Appendix V. By reporting side effects you can help provide more information on the safety of
this medicine.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store lyfnua"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store lyfnua"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and the carton after  EXP .
The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not use this medicine if you notice that the packaging is damaged or shows signs of tampering.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the environment.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Lyfnua contains
The active substance is gefapixant. Each film-coated tablet contains 45 mg gefapixant (as citrate).
The other ingredients are silica (colloidal anhydrous) (E551), crospovidone (E1202), hypromellose
(E464), magnesium stearate (E470b), mannitol (E421), microcrystalline cellulose (E460), sodium
stearyl fumarate. The tablets are film-coated with a coating material containing the following
ingredients: hypromellose (E464), titanium dioxide (E171), triacetin (E1518) and red ferric oxide
(E172). The tablets are polished with carnauba wax (E903).
What Lyfnua looks like and contents of the pack
Lyfnua is a pink, round and convex tablet, debossed with 777 on one side and plain on the other side.
Lyfnua is available in white PVC/PE/PVdC blisters. 
Lyfnua is available in packs containing 28, 56 and 98 film-coated tablets in non-perforated blisters
(14 tablets per card), multipacks containing 196 (2 packs of 98) film coated tables in non-perforated
blisters.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer 
Merck Sharp &amp; Dohme B.V.
Waarderweg 2031 BN Haarlem
The Netherlands
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
Belgi /Belgique/Belgien
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel. + 370 5 278 02 msd_lietuva@merck.com</p>
<p>.: +359 2 819 3info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
 esk  republika
Merck Sharp &amp; Dohme s.r.o.
Tel: +420 233 010 dpoc_czechslovak@merck.com
Magyarorsz g
MSD Pharma Hungary Kft. 
Tel.: +36 1 888 5hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: + 45 4482 4dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999(+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme O 
Tel.: +372 6144 msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 msdnorge@msd.no</p>
<p>MSD  . . . . .
 : +30 210 98 97 dpoc_greece@merck.com
 sterreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 dpoc_austria@merck.com
Espa a
Merck Sharp &amp; Dohme de Espa a, S.A.
Tel: +34 91 321 06 msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel: +48 22 549 51 msdpolska@merck.com
France
MSD France
T l: + 33 (0) 1 80 46 40 Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: + 385 1 6611 croatia_info@merck.com
Rom nia
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: +40 21 529 29 msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila
d.o.o.
Tel: +386 1 5204 msd.slovenia@merck.com
 sland
Vistor hf.
S mi: + 354 535 7Slovensk  republika
Merck Sharp &amp; Dohme, s. r. o.
Tel: +421 2 58282dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 info@msd.fi</p>
<p>Merck Sharp &amp; Dohme Cyprus Limited
 .: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: + 371 67364msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfoNI@msd.com
This leaflet was last revised in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu</p> </div>"""      



Instance: composition-da-d5d0f8dae3251797998b53d83d0b35fa
InstanceOf: CompositionUvEpi
Title: "Composition for lyfnua Package Leaflet"
Description:  "Composition for lyfnua Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/21/1613/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd5d0f8dae3251797998b53d83d0b35fa)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - lyfnua"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Lyfnua
3. Sådan skal du tage Lyfnua
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lyfnua indeholder det aktive stof gefapixant.
Lyfnua er et lægemiddel, der anvendes til voksne mod kronisk hoste (hoste, som varer længere end
8 uger) og: </p>
<ul>
<li>
<p>hosten forsvinder ikke selv efter brug af andre lægemidler eller </p>
</li>
<li>
<p>årsagen til hosten er ukendt.
Det aktive stof i Lyfnua, gefapixant, blokerer virkningen af de nerver, som udløser unormal hoste.</p>
</li>
</ul> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  lyfnua"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  lyfnua"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Lyfnua
- hvis du er allergisk over for gefapixant eller et af de øvrige indholdsstoffer i Lyfnua (angivet i
punkt 6).
Advarsler og forsigtighedsregler
Kontakt lægen eller apotekspersonalet, før og mens du tager Lyfnua, hvis du:</p>
<ul>
<li>er allergisk over for lægemidler indeholdende sulfonamid</li>
<li>har søvnapnø - hvor din vejrtrækning stopper og starter, mens du sover</li>
<li>udvikler en akut infektion i lunger / nedre luftveje (f.eks. lungebetændelse eller bronkitis)</li>
<li>oplever ændret smagssans, tab af smagssans eller at være mindre i stand til at smage, som
fortsætter selv efter, at du er holdt op med at tage Lyfnua 
26
Børn og unge 
Giv ikke dette lægemiddel til børn og unge under 18 år. Det skyldes, at lægemidlet ikke er undersøgt i
denne aldersgruppe.
Brug af andre lægemidler sammen med Lyfnua
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget
andre lægemidler eller planlægger at tage andre lægemidler.
Graviditet og amning 
Det er ukendt, om Lyfnua kan skade dit ufødte barn. Derfor er det bedst at undgå at tage Lyfnua, hvis
du er gravid. 
Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge
lægen eller apotekspersonalet til råds, før du tager dette lægemiddel.
Dyreforsøg har vist, at Lyfnua kan udskilles i modermælk. En risiko for din baby kan ikke udelukkes.
Du og din læge skal sammen beslutte, om du skal tage Lyfnua eller amme.
Trafik- og arbejdssikkerhed
Du kan føle dig svimmel efter at have taget Lyfnua. Du må ikke føre motorkøretøj eller betjene
maskiner, hvis du føler dig svimmel. 
Lyfnua indeholder natrium
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det
væsentlige natriumfrit.</li>
</ul> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage lyfnua"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage lyfnua"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg
lægen eller apotekspersonalet.
Så meget skal du tage
Den anbefalede dosis af Lyfnua er:</p>
<ul>
<li>
<p>en 45 mg tablet to gange dagligt.
Voksne med nyreproblemer
Din læge kan ændre, hvor meget og hvor ofte du tager Lyfnua, hvis:</p>
</li>
<li>
<p>du har alvorligt nyresvigt og ikke er i dialyse.
Sådan skal du tage
Slug tabletten hel. Du må ikke dele, knuse eller tygge tabletten. 
Tabletten kan tages med eller uden mad. 
Hvis du har taget for meget Lyfnua
Kontakt straks lægen eller apotekspersonalet, hvis du har taget for meget Lyfnua.
Hvis du har glemt at tage Lyfnua
Hvis du har glemt en dosis, så spring denne over og tag den næste dosis til den planlagte tid. 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. 
27</p>
</li>
</ul> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
De mulige bivirkninger er:
Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer)
- smagsforstyrrelser (såsom: metallisk, bitter eller saltet smag)
- nedsat smagssans
- tab af smagssans
Almindelige (kan forekomme hos op til 1 ud af 10 personer)
- kvalme
- ting smager anderledes end de plejer
- hoste (forværret hoste, øget hostetendens)
- tør mund
- øvre luftvejsinfektion (en infektion i den øvre del af luftvejene, inklusive næse og svælg)
- diarré
- smerter i mund eller hals
- mindre appetit, end du plejer
- svimmelhed
- smerter i øvre del af maven
- fordøjelsesbesvær
- usædvanlig følelse i munden (f.eks. snurrende eller prikkende følelse)
- tab af følelse i munden
- øget spytproduktion
- insomni (søvnbesvær)
Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer)
- blære-, urinvejs- eller nyresten
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med lægen eller apotekspersonalet. Dette gælder også mulige
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om
sikkerheden af dette lægemiddel.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Tag ikke lægemidlet efter den udløbsdato, der står på blister og karton efter EXP. Udløbsdatoen er den
sidste dag i den nævnte måned.
Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
Tag ikke lægemidlet, hvis du bemærker, at emballagen er beskadiget eller viser tegn på anbrud. 
Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden.
28</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lyfnua indeholder:</p>
<ul>
<li>Aktivt stof: gefapixant Hver filmovertrukken tablet indeholder 45 mg gefapixant (som citrat).</li>
<li>Øvrige indholdsstoffer: silica (kolloid vandfri) (E551), crospovidon (E1202),
hypromellose (E464), magnesiumstearat (E470b), mannitol (E421), mikrokrystallinsk
cellulose (E460), natriumstearylfumarat. Tabletterne er filmovertrukne med et
overtræksmateriale med følgende indholdsstoffer: hypromellose (E464), titandioxid (E171),
triacetin (E1518) og rød jernoxid (E172). Tabletterne er polerede med carnaubavoks (E903). 
Udseende og pakningsstørrelser
Lyfnua er en lyserød, rund og konveks tablet præget med 777 på den ene side og uden prægning på
den anden side. 
Lyfnua fås i hvide PVC/PE/PVdC blistre.
Lyfnua fås i pakninger med 28, 56 og 98 filmovertrukne tabletter i ikke-perforerede blistre
(14 tabletter pr. blister), multipakninger indeholdende 196 (2 pakninger a 98) filmovertrukne tabletter i
ikke-perforerede blistre.
Ikke alle pakningstørrelser er nødvendigvis markedsført. 
Indehaver af markedsføringstilladelsen og fremstiller
Merck Sharp &amp; Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Holland
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
Lietuva 
UAB Merck Sharp &amp; Dohme
Tel. + 370 5 278 02 47
msd_lietuva@merck.com
България
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3737
info-msdbg@merck.com
Luxembourg/Luxemburg 
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
Česká republika
Merck Sharp &amp; Dohme s.r.o.
Tel: +420 233 010 dpoc_czechslovak@merck.com
Magyarország 
MSD Pharma Hungary Kft. 
Tel.: +36 1 888 5300
hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf.: + 45 4482 4000
dkmail@merck.com
Malta 
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
29
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland 
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999(+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme OÜ
Tel.: +372 6144 200
msdeesti@merck.com
Norge 
MSD (Norge) AS
Tlf: +47 32 20 73 00
msdnorge@msd.no
Ελλάδα
MSD Α .Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
dpoc_greece@merck.com
Österreich 
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@merck.com
España
Merck Sharp &amp; Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@merck.com
Polska 
MSD Polska Sp. z o.o.
Tel: +48 22 549 51 00
msdpolska@merck.com
France
MSD France
Tél: + 33 (0) 1 80 46 40 40
Portugal 
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465700
inform_pt@merck.com
Hrvatska
Merck Sharp &amp; Dohme d.o.o.
Tel: + 385 1 6611 333
croatia_info@merck.com
România 
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: +40 21 529 29 00
msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfo_ireland@merck.com
Slovenija 
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386 1 5204 201
msd.slovenia@merck.com
Ísland
Vistor hf.
Sími: + 354 535 7000
Slovenská republika 
Merck Sharp &amp; Dohme, s. r. o.
Tel: +421 2 58282010
dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland 
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi
Κύπρος
Merck Sharp &amp; Dohme Cyprus Limited
Τηλ.: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige 
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@merck.com
30
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: + 371 67364224
msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfoNI@msd.com
Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}.
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs
hjemmeside http://www.ema.europa.eu. </li>
</ul> </div>"""      





                    
Instance: bundlepackageleaflet-en-d5d0f8dae3251797998b53d83d0b35fa
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for lyfnua Package Leaflet for language en"
Description: "ePI document Bundle for lyfnua Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-d5d0f8dae3251797998b53d83d0b35fa"
* entry[0].resource = composition-en-d5d0f8dae3251797998b53d83d0b35fa

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd5d0f8dae3251797998b53d83d0b35fa"
* entry[=].resource = mpd5d0f8dae3251797998b53d83d0b35fa
                            
                    
Instance: bundlepackageleaflet-da-d5d0f8dae3251797998b53d83d0b35fa
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for lyfnua Package Leaflet for language da"
Description: "ePI document Bundle for lyfnua Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-d5d0f8dae3251797998b53d83d0b35fa"
* entry[0].resource = composition-da-d5d0f8dae3251797998b53d83d0b35fa

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd5d0f8dae3251797998b53d83d0b35fa"
* entry[=].resource = mpd5d0f8dae3251797998b53d83d0b35fa
                            
                    



Instance: mpd5d0f8dae3251797998b53d83d0b35fa
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Lyfnua 45 mg film-coated tablets"
Description: "Lyfnua 45 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1613/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Lyfnua 45 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: d5d0f8dae3251797998b53d83d0b35faListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "lyfnua"

* status = #current
* mode = #working

* title = "List of all ePIs associated with lyfnua"

* subject = Reference(mpd5d0f8dae3251797998b53d83d0b35fa)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#lyfnua "lyfnua"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-d5d0f8dae3251797998b53d83d0b35fa) // lyfnua en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-d5d0f8dae3251797998b53d83d0b35fa) // lyfnua da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-d5d0f8dae3251797998b53d83d0b35fa
InstanceOf: List
Description: "ePI document List for lyfnua Package Leaflets"

* insert d5d0f8dae3251797998b53d83d0b35faListRuleset
    